1. Home
  2. FSHP vs MDXH Comparison

FSHP vs MDXH Comparison

Compare FSHP & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSHP
  • MDXH
  • Stock Information
  • Founded
  • FSHP 2018
  • MDXH 2003
  • Country
  • FSHP United States
  • MDXH Belgium
  • Employees
  • FSHP N/A
  • MDXH N/A
  • Industry
  • FSHP
  • MDXH
  • Sector
  • FSHP
  • MDXH
  • Exchange
  • FSHP NYSE
  • MDXH Nasdaq
  • Market Cap
  • FSHP 90.8M
  • MDXH 93.1M
  • IPO Year
  • FSHP 2024
  • MDXH 2021
  • Fundamental
  • Price
  • FSHP $10.23
  • MDXH $1.83
  • Analyst Decision
  • FSHP
  • MDXH Strong Buy
  • Analyst Count
  • FSHP 0
  • MDXH 2
  • Target Price
  • FSHP N/A
  • MDXH $7.00
  • AVG Volume (30 Days)
  • FSHP 7.5K
  • MDXH 77.7K
  • Earning Date
  • FSHP 01-01-0001
  • MDXH 02-26-2025
  • Dividend Yield
  • FSHP N/A
  • MDXH N/A
  • EPS Growth
  • FSHP N/A
  • MDXH N/A
  • EPS
  • FSHP 0.11
  • MDXH N/A
  • Revenue
  • FSHP N/A
  • MDXH $84,708,000.00
  • Revenue This Year
  • FSHP N/A
  • MDXH $28.76
  • Revenue Next Year
  • FSHP N/A
  • MDXH $19.91
  • P/E Ratio
  • FSHP $90.08
  • MDXH N/A
  • Revenue Growth
  • FSHP N/A
  • MDXH 33.01
  • 52 Week Low
  • FSHP $9.99
  • MDXH $1.55
  • 52 Week High
  • FSHP $10.25
  • MDXH $3.85
  • Technical
  • Relative Strength Index (RSI)
  • FSHP N/A
  • MDXH 35.99
  • Support Level
  • FSHP N/A
  • MDXH $1.73
  • Resistance Level
  • FSHP N/A
  • MDXH $1.90
  • Average True Range (ATR)
  • FSHP 0.00
  • MDXH 0.08
  • MACD
  • FSHP 0.00
  • MDXH -0.00
  • Stochastic Oscillator
  • FSHP 0.00
  • MDXH 37.04

About FSHP FLAG SHIP ACQUISITION CORPORATION

Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.

Share on Social Networks: